The Congressional Budget Office said policies to increase treatment uptake could affect Medicaid, Social Security, and other government programs.

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

It’s similar in concept to Casgevy, an approved medicine from Vertex Pharmaceuticals, but uses a different form of DNA ...

We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are ...

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.84% higher to $402.70 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.43 ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

A cognitive behavioral intervention eased chronic pain for people with kidney failure on maintenance hemodialysis, a ...

Precision Medicine Online readers were interested in stories about implementation challenges in the space, the first cell therapies for solid tumors, and cardiovascular drugs targeting Lp(a).

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...